P Selectin - Pipeline Review, H2 2019
P Selectin - Pipeline Review, H2 2019
SUMMARY
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) pipeline Target constitutes close to 7 molecules. The latest report P Selectin - Pipeline Review, H2 2019, outlays comprehensive information on the P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - P-selectin is a protein encoded by the SELP gene. P-selectin functions as a cell adhesion molecule (CAM) on the surfaces of activated endothelial cells. In unactivated endothelial cells, it is stored in granules called Weibel-Palade bodies. In unactivated platelets P-selectin is stored in alpha-granules. P-selectin plays an essential role in the initial recruitment of leukocytes (white blood cells) to the site of injury during inflammation. The molecules developed by companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 1, 1, 4 and 1 respectively. Report covers products from therapy areas Cardiovascular, Oncology, Ear Nose Throat Disorders, Central Nervous System, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Hematological Disorders, Immunology, Mouth and Dental Disorders and Respiratory which include indications Vaso-Occlusive Crisis Associated With Sickle Cell Disease, Rhinosinusitis, Asthma, Chronic Kidney Disease (Chronic Renal Failure), Head And Neck Cancer, Inflammation, Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Oral Mucositis, Periodontitis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Rosacea and Sickle Cell Disease.
Furthermore, this report also reviews key players involved in P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) pipeline Target constitutes close to 7 molecules. The latest report P Selectin - Pipeline Review, H2 2019, outlays comprehensive information on the P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - P-selectin is a protein encoded by the SELP gene. P-selectin functions as a cell adhesion molecule (CAM) on the surfaces of activated endothelial cells. In unactivated endothelial cells, it is stored in granules called Weibel-Palade bodies. In unactivated platelets P-selectin is stored in alpha-granules. P-selectin plays an essential role in the initial recruitment of leukocytes (white blood cells) to the site of injury during inflammation. The molecules developed by companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 1, 1, 4 and 1 respectively. Report covers products from therapy areas Cardiovascular, Oncology, Ear Nose Throat Disorders, Central Nervous System, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Hematological Disorders, Immunology, Mouth and Dental Disorders and Respiratory which include indications Vaso-Occlusive Crisis Associated With Sickle Cell Disease, Rhinosinusitis, Asthma, Chronic Kidney Disease (Chronic Renal Failure), Head And Neck Cancer, Inflammation, Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Oral Mucositis, Periodontitis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Rosacea and Sickle Cell Disease.
Furthermore, this report also reviews key players involved in P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP)
- The report reviews P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics and enlists all their major and minor projects
- The report assesses P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Overview
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Companies Involved in Therapeutics Development
Global Blood Therapeutics Inc
GlycoMira Therapeutics Inc
Novartis AG
Pfizer Inc
Tumorend LLC
Vanguard Therapeutics Inc
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Drug Profiles
crizanlizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-1111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inclacumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rivipansel sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit P and L Selectins for Inflammation and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Dormant Products
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Discontinued Products
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Product Development Milestones
Featured News & Press Releases
Dec 02, 2019: Novartis to present abstract on Adakveo (crizanlizumab) at American Society of Hematology Annual Meeting & Exposition (ASH) 2019
Nov 18, 2019: FDA approves Novartis’ Adakveo for sickle cell disease patients
Aug 05, 2019: Pfizer’s RESET trial of rivipansel fails to meet endpoints
Jul 16, 2019: FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
May 06, 2019: GlycoMimetics announces enrollment completed for phase 3 clinical trial evaluating Rivipansel in Sickle Cell Disease
Jan 09, 2019: FDA grants breakthrough therapy status to crizanlizumab
Dec 01, 2018: Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
Nov 05, 2018: Novartis provides update on SEG101
Nov 02, 2018: Novartis to present new data on Crizanlizumab at 2018 ASH annual meeting
Oct 09, 2018: Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
Jun 14, 2018: New Hope in the Fight Against Sickle Cell Disease
Dec 11, 2017: Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
Feb 01, 2017: A multiple drug approach to preventing sickle cell crisis
Dec 03, 2016: Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study
Oct 29, 2015: GlycoMimetics Announces Initiation of First Clinical Trial Evaluating Subcutaneous Administration of Rivipansel
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Overview
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Companies Involved in Therapeutics Development
Global Blood Therapeutics Inc
GlycoMira Therapeutics Inc
Novartis AG
Pfizer Inc
Tumorend LLC
Vanguard Therapeutics Inc
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Drug Profiles
crizanlizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-1111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inclacumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rivipansel sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit P and L Selectins for Inflammation and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Dormant Products
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Discontinued Products
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Product Development Milestones
Featured News & Press Releases
Dec 02, 2019: Novartis to present abstract on Adakveo (crizanlizumab) at American Society of Hematology Annual Meeting & Exposition (ASH) 2019
Nov 18, 2019: FDA approves Novartis’ Adakveo for sickle cell disease patients
Aug 05, 2019: Pfizer’s RESET trial of rivipansel fails to meet endpoints
Jul 16, 2019: FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
May 06, 2019: GlycoMimetics announces enrollment completed for phase 3 clinical trial evaluating Rivipansel in Sickle Cell Disease
Jan 09, 2019: FDA grants breakthrough therapy status to crizanlizumab
Dec 01, 2018: Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
Nov 05, 2018: Novartis provides update on SEG101
Nov 02, 2018: Novartis to present new data on Crizanlizumab at 2018 ASH annual meeting
Oct 09, 2018: Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
Jun 14, 2018: New Hope in the Fight Against Sickle Cell Disease
Dec 11, 2017: Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
Feb 01, 2017: A multiple drug approach to preventing sickle cell crisis
Dec 03, 2016: Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study
Oct 29, 2015: GlycoMimetics Announces Initiation of First Clinical Trial Evaluating Subcutaneous Administration of Rivipansel
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Global Blood Therapeutics Inc, H2 2019
Pipeline by GlycoMira Therapeutics Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Tumorend LLC, H2 2019
Pipeline by Vanguard Therapeutics Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Global Blood Therapeutics Inc, H2 2019
Pipeline by GlycoMira Therapeutics Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Tumorend LLC, H2 2019
Pipeline by Vanguard Therapeutics Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Global Blood Therapeutics Inc
GlycoMira Therapeutics Inc
Novartis AG
Pfizer Inc
Tumorend LLC
Vanguard Therapeutics Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Global Blood Therapeutics Inc
GlycoMira Therapeutics Inc
Novartis AG
Pfizer Inc
Tumorend LLC
Vanguard Therapeutics Inc
